跳转至内容
Merck
CN

Novel mechanism of JNK pathway activation by adenoviral E1A.

Oncotarget (2014-04-20)
Vasily S Romanov, Anna I Brichkina, Helen Morrison, Tatiana V Pospelova, Valery A Pospelov, Peter Herrlich
摘要

The adenoviral oncoprotein E1A influences cellular regulation by interacting with a number of cellular proteins. In collaboration with complementary oncogenes, E1A fully transforms primary cells. As part of this action, E1A inhibits transcription of c-Jun:Fos target genes while promoting that of c-Jun:ATF2-dependent genes including jun. Both c-Jun and ATF2 are hyperphosphorylated in response to E1A. In the current study, E1A was fused with the ligand binding domain of the estrogen receptor (E1A-ER) to monitor the immediate effect of E1A activation. With this approach we now show that E1A activates c-Jun N-terminal kinase (JNK), the upstream kinases MKK4 and MKK7, as well as the small GTPase Rac1. Activation of the JNK pathway requires the N-terminal domain of E1A, and, importantly, is independent of transcription. In addition, it requires the presence of ERM proteins. Downregulation of signaling components upstream of JNK inhibits E1A-dependent JNK/c-Jun activation. Taking these findings together, we show that E1A activates the JNK/c-Jun signaling pathway upstream of Rac1 in a transcription-independent manner, demonstrating a novel mechanism of E1A action.

材料
Product Number
品牌
产品描述

Sigma-Aldrich
SP600125, ≥98% (HPLC)
Sigma-Aldrich
抗Rac1抗体,克隆23A8, clone 23A8, Upstate®, from mouse
Sigma-Aldrich
抗Myc标签抗体, Upstate®, from rabbit